GLENMARK.NS : Summary for GLENMARK PHARM INR1.00 - Yahoo Finance

U.S. Markets open in 13 mins.

Glenmark Pharmaceuticals Limited (GLENMARK.NS)


NSE - NSE Real Time Price. Currency in INR
Add to watchlist
881.80-21.75 (-2.41%)
At close: 3:29PM IST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close903.55
Open899.50
Bid881.80 x
Ask0.00 x
Day's Range875.35 - 899.75
52 Week Range730.00 - 994.00
Volume249,201
Avg. Volume486,268
Market Cap248.97B
BetaN/A
PE Ratio (TTM)23.92
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters2 years ago

    India's Glenmark bets on US sales to offset emerging markets weakness

    Indian drugmaker Glenmark Pharmaceuticals is counting on strong growth in the United States, where it will launch a dozen new medicines, to offset weakness in emerging markets this year, its chief executive said. One of India's top 10 drugmakers by sales, Glenmark has seen its profit hit in recent quarters by currency volatility in Russia, Venezuela and other emerging markets, after a steep decline in oil prices and China's devaluation of the yuan. "Our U.S. business right now is more than compensating for the hit we are taking in emerging markets," Glenn Saldanha said on the sidelines of the company's annual general meeting in Mumbai.

  • Reuters2 years ago

    As stocks tumble, Indian pharma, Taiwan tech lure smart money

    Asia's tumbling stocks have triggered an exodus of funds from the region, but some investors say the sell-off has been indiscriminate and that certain stocks offer compelling buying opportunities. The downturn in equities has been exacerbated by steep falls in Asian currencies, which have taken multiple blows from a sputtering Chinese economy, the unexpected 2 percent devaluation of its yuan currency on Aug. 11, and expectations the U.S. Federal Reserve will raise rates by year-end. Fears the China growth woes could knock the global economy have spread turmoil in world financial markets, toppling the benchmark MSCI Asia Pacific ex-Japan index 16 percent this year.

  • Reuters2 years ago

    Indian court bars Glenmark from selling Merck drug copies

    India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of U.S. drugmaker Merck's diabetes drugs Januvia and Janumet, according to a court document released on Friday. The court has, however, allowed Glenmark to continue to sell existing inventory, according to the document posted on the Supreme Court's website after a hearing. The decision against Glenmark comes two years after Switzerland's Novartis AG was denied patent protection for its cancer treatment Glivec in a landmark decision by India's Supreme Court that was widely seen as boosting the local generic drugs industry.